Boston Scientific (BSX) reported Q3 EPS of $0.43, $0.01 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $3.17 billion versus the consensus estimate of $3.15 billion.
GUIDANCE:
Boston Scientific sees Q4 2022 EPS of $0.45-$0.48, versus the consensus of $0.49.
Boston Scientific sees FY2022 EPS of $1.71-$1.74, versus the consensus of $1.76.